Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Biogen has a “Moderate Buy” consensus among 33 analysts: 18 recommend buying, one rates it a strong buy, 13 recommend holding, and one recommends selling. The average 12-month price target is approximately $230.14.
• Recent analysts raised their price targets, including RBC to $260, HC Wainwright to $251, Barclays to $200, and Wedbush to $215, reflecting generally favorable but mixed expectations.
• Biogen exceeded quarterly estimates, reporting $3.60 in EPS versus the $2.94 consensus and $2.74 billion in revenue versus $2.46 billion expected. Institutional investors own 87.93% of the company, with BlackRock recently taking a major position.

Biogen Inc. (NASDAQ:BIIB - Get Free Report) has received an average rating of "Moderate Buy" from the thirty-three research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, eighteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $230.1429.

Several analysts have commented on the stock. Royal Bank Of Canada lifted their target price on shares of Biogen from $240.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 25th. HC Wainwright increased their target price on shares of Biogen from $237.00 to $251.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Barclays lifted their price target on shares of Biogen from $185.00 to $200.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 29th. Weiss Ratings downgraded shares of Biogen from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, August 12th. Finally, Wedbush upped their price target on shares of Biogen from $201.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, July 30th.

Biogen Stock Performance

Shares of BIIB opened at $217.36 on Tuesday. The company has a 50-day simple moving average of $209.75 and a 200-day simple moving average of $197.53. The company has a market capitalization of $32.11 billion, a PE ratio of 38.47, a P/E/G ratio of 2.40 and a beta of 0.17. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 52-week low of $135.39 and a 52-week high of $225.80.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts predict that Biogen will post 12.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Biogen in the 2nd quarter valued at about $3,453,878,000. Orbimed Advisors LLC acquired a new stake in shares of Biogen in the 1st quarter worth approximately $11,293,000. LSV Asset Management lifted its stake in shares of Biogen by 3.3% in the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company's stock worth $55,756,000 after acquiring an additional 9,976 shares during the period. Catalyst Funds Management Pty Ltd bought a new position in shares of Biogen in the fourth quarter valued at approximately $2,006,000. Finally, Systematic Financial Management LP increased its stake in shares of Biogen by 256.3% during the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company's stock valued at $2,928,000 after acquiring an additional 11,970 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen's portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.